MXPA04005207A - Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. - Google Patents

Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.

Info

Publication number
MXPA04005207A
MXPA04005207A MXPA04005207A MXPA04005207A MXPA04005207A MX PA04005207 A MXPA04005207 A MX PA04005207A MX PA04005207 A MXPA04005207 A MX PA04005207A MX PA04005207 A MXPA04005207 A MX PA04005207A MX PA04005207 A MXPA04005207 A MX PA04005207A
Authority
MX
Mexico
Prior art keywords
manufacture
antineoplastic agents
farsenyl
combination
against cancer
Prior art date
Application number
MXPA04005207A
Other languages
English (en)
Spanish (es)
Inventor
Sara L Zaknoen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA04005207A publication Critical patent/MXPA04005207A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA04005207A 2001-11-30 2002-11-25 Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. MXPA04005207A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
PCT/US2002/037954 WO2003047697A2 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Publications (1)

Publication Number Publication Date
MXPA04005207A true MXPA04005207A (es) 2004-08-19

Family

ID=23307076

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005207A MXPA04005207A (es) 2001-11-30 2002-11-25 Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.

Country Status (13)

Country Link
US (2) US20030185831A1 (enExample)
EP (1) EP1448268A2 (enExample)
JP (1) JP2005511663A (enExample)
CN (2) CN1617755A (enExample)
AU (1) AU2002352941A1 (enExample)
BR (1) BR0214564A (enExample)
CA (1) CA2468839A1 (enExample)
HU (1) HUP0402401A2 (enExample)
MX (1) MXPA04005207A (enExample)
NO (1) NO20042730L (enExample)
NZ (1) NZ532562A (enExample)
WO (1) WO2003047697A2 (enExample)
ZA (1) ZA200403737B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498982A1 (en) * 2002-07-24 2004-01-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
BRPI0416316A (pt) * 2003-11-06 2007-01-09 Schering Corp combinação de um inibidor da farnesil transferase com um agente anti-hormonal para o tratamento de cáncer de mama
CA2557504C (en) * 2004-02-26 2020-12-01 The Penn State Research Foundation Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
JP2009511450A (ja) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ
US20100104661A1 (en) * 2006-10-25 2010-04-29 Susan Arbuck Discontinuous methods of treating cancer
US20100069411A1 (en) * 2006-11-28 2010-03-18 Smithkline Beecham (Cork) Ltd. Cancer treatment method
KR20230098281A (ko) * 2020-10-27 2023-07-03 위스콘신 얼럼나이 리서어치 화운데이션 조합 면역요법을 위한 모듈형 덴드론 미셀
EP4615842A1 (en) 2022-11-09 2025-09-17 Merck Patent GmbH Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
PT1041985E (pt) * 1997-12-22 2006-07-31 Schering Corp Combinacao de compostos benzociclo-heptapiridina e farmacos antineoplasicos para tratar doencas proliferativas
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
PT1255537E (pt) * 2000-02-04 2006-09-29 Janssen Pharmaceutica Nv Inibidores da proteina farnesil transferase para tratar cancro da mama
JP2003523381A (ja) * 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
US20030181473A1 (en) * 2000-02-29 2003-09-25 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001244166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
MXPA03003011A (es) * 2000-10-05 2003-07-14 George Q Daley Metodos para inducir muerte de celulas cancerosas y regresion de tumores.

Also Published As

Publication number Publication date
US20030185831A1 (en) 2003-10-02
BR0214564A (pt) 2004-11-09
US20060183765A1 (en) 2006-08-17
EP1448268A2 (en) 2004-08-25
JP2005511663A (ja) 2005-04-28
CN101181269A (zh) 2008-05-21
NZ532562A (en) 2007-02-23
AU2002352941A1 (en) 2003-06-17
WO2003047697A3 (en) 2003-10-30
CA2468839A1 (en) 2003-06-12
ZA200403737B (en) 2005-05-23
WO2003047697A2 (en) 2003-06-12
CN1617755A (zh) 2005-05-18
HUP0402401A2 (hu) 2005-03-29
NO20042730L (no) 2004-06-29

Similar Documents

Publication Publication Date Title
MXPA04005425A (es) Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer.
YU77000A (sh) Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c
WO2025049814A3 (en) Ribonucleotide reductase (rnr) compositions and methods of use
NZ544472A (en) Compounds and therapeutical use thereof
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
MXPA01004648A (es) Tratamientro de enfermedades hematologicas malignas asociadas con celulas tumorales de la circulacion usando el anticuerpo quimerico anti-cd20.
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
MY138883A (en) Use of asiatic acid for treatment of cencer
IL155781A0 (en) Effective antitumor treatments
WO2002102306A3 (en) Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
MY164077A (en) Compositions and uses of et743 for treating cancer
ZA200703396B (en) Pegylated Liposomal Doxorubicin in combination with Ecteinascidin 743
WO2004012662A3 (en) Improved treatment of cancer with glutamine
IL150953A0 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
WO2003047697A3 (en) Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
PL1689404T3 (pl) Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
GB0020504D0 (en) Therapeutic method
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
PL1603584T3 (pl) Aplidyna do leczenia szpiczaka mnogiego
IL159770A0 (en) Calcium salts with cytotoxic activity
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents